Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
ATLANTIS is a multicenter, phase IIIb, prospective, open-label, randomized trial. The objective of this study is to demonstrate superiority of a strategy of anticoagulation with apixaban (Anti-Xa Group) as compared to the current standard of care in patients who have undergone a successful TAVI procedure. The randomization is stratified according to the presence or not of a mandatory indication for anticoagulation for a reason other than the TAVI procedure (e.g. atrial fibrillation or DVT/PE).
Epistemonikos ID: fb1eacaec0df74d3e4c5ff11c989e8111e893105
First added on: May 12, 2024